Pharmacovigilance Programme of India

Last updated

Pharmacovigilance Programme of India
Organisation overview
Formed2010 (2010)[ citation needed ]
TypeRegulatory body
Parent department Indian Pharmacopoeia Commission
Website cdsco.gov.in/opencms/opencms/en/PvPI/

The Pharmacovigilance Programme of India (PvPI) is an Indian government organization which identifies and responds to drug safety problems. [1] Its activities include receiving reports of adverse drug events and taking necessary action to remedy problems. [1] The Central Drugs Standard Control Organisation established the program in July 2010 [1] [2] with All India Institute of Medical Sciences, New Delhi as the National Coordination Centre, which later shifted to Indian Pharmacopoeia Commission in Ghaziabad on 15 April 2011. [1] [2]

Contents

History

Many developed countries set up their pharmacovigilance programs following the Thalidomide scandal in the 1960s. [2] India set up its program in the 1980s. [2] This general concept of drug safety monitoring went through different forms, but the Central Drugs Standard Control Organisation established the present Pharmacovigilance Program of India in 2010. [2] Now the program is well integrated with government legislation, a regulator as leader, and a research center as part of the Indian Pharmacopoeia Commission. [2]

Activities

As of 2018 there were 250 centers around India capable of responding to reports of serious adverse reactions. [2] One of the challenges of the organization is training doctors and hospitals to report adverse drug reactions when patients have them. [3] The Pharmacovigilance Program makes these reports itself, but ideally, such reports could originate from any clinic. [3] The Pharmacovigilance Programme seeks to encourage a culture and social expectation of reporting drug problems. [3]

One of the successes of the program was detecting adverse effects of people in India using carbamazepine. [3] [4] While this drug is safer among people native to the Europe, people of South Asia have different genetics and are more likely to experience problems when using it. [3] [4] Other countries could not have been able to detect this problem, and the Pharmacovigilance Programme's detection of it was a success story. [3] [4]

Collaboration

The establishment of the Pharmacovigilance Program made India a more attractive international destination for foreign companies to bring clinical trials research. [5] Understanding the quality of India's pharmacovigilance programme is key to international researchers conducting trials in India. [6]

The program collaborates both in India and internationally with the World Health Organization on projects for safe medication. [7] [2] As a collaborating center, the Pharmacovigilance Programme assists the WHO in developing international policy for other countries to manage their own drug safety programs. [7]

While the United States and Europe have pharmacovigilance systems which are developed well in some ways, the Indian programme has more and specialized expertise to apply for the unique circumstances of India. [8] The Pharmaceutical industry in India produces more drugs than any other national industry. [8] Because of the large amount of drugs and the many countries which import them, the Indian program monitors in some ways more than anywhere else. [8]

Related Research Articles

<span class="mw-page-title-main">Regulation of therapeutic goods</span> Legal management of drugs and restricted substances

The regulation of therapeutic goods, defined as drugs and therapeutic devices, varies by jurisdiction. In some countries, such as the United States, they are regulated at the national level by a single agency. In other jurisdictions they are regulated at the state level, or at both state and national levels by various bodies, as in Australia.

Pharmacovigilance, also known as drug safety, is the pharmaceutical science relating to the "collection, detection, assessment, monitoring, and prevention" of adverse effects with pharmaceutical products. The etymological roots for the word "pharmacovigilance" are: pharmakon and vigilare. As such, pharmacovigilance heavily focuses on adverse drug reactions (ADR), which are defined as any response to a drug which is noxious and unintended, including lack of efficacy. Medication errors such as overdose, and misuse and abuse of a drug as well as drug exposure during pregnancy and breastfeeding, are also of interest, even without an adverse event, because they may result in an adverse drug reaction.

<span class="mw-page-title-main">Adverse drug reaction</span> Medical condition

An adverse drug reaction (ADR) is a harmful, unintended result caused by taking medication. ADRs may occur following a single dose or prolonged administration of a drug or may result from the combination of two or more drugs. The meaning of this term differs from the term "side effect" because side effects can be beneficial as well as detrimental. The study of ADRs is the concern of the field known as pharmacovigilance. An adverse event (AE) refers to any unexpected and inappropriate occurrence at the time a drug is used, whether or not the event is associated with the administration of the drug. An ADR is a special type of AE in which a causative relationship can be shown. ADRs are only one type of medication-related harm. Another type of medication-related harm type includes not taking prescribed medications, which is also known as non-adherence. Non-adherence to medications can lead to death and other negative outcomes. Adverse drug reactions require the use of a medication.

An adverse effect is an undesired harmful effect resulting from a medication or other intervention, such as surgery. An adverse effect may be termed a "side effect", when judged to be secondary to a main or therapeutic effect. The term complication is similar to adverse effect, but the latter is typically used in pharmacological contexts, or when the negative effect is expected or common. If the negative effect results from an unsuitable or incorrect dosage or procedure, this is called a medical error and not an adverse effect. Adverse effects are sometimes referred to as "iatrogenic" because they are generated by a physician/treatment. Some adverse effects occur only when starting, increasing or discontinuing a treatment. Adverse effects can also be caused by placebo treatments . Using a drug or other medical intervention which is contraindicated may increase the risk of adverse effects. Adverse effects may cause complications of a disease or procedure and negatively affect its prognosis. They may also lead to non-compliance with a treatment regimen. Adverse effects of medical treatment resulted in 142,000 deaths in 2013 up from 94,000 deaths in 1990 globally.

<span class="mw-page-title-main">Nimesulide</span> Anti-inflammatory drug

Nimesulide is a nonsteroidal anti-inflammatory drug (NSAID) with pain medication and fever reducing properties. Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis, and primary dysmenorrhoea in adolescents and adults above 12 years old.

An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

A serious adverse event (SAE) in human drug trials is defined as any untoward medical occurrence that at any dose

  1. Results in death
  2. Is life-threatening
  3. Requires inpatient hospitalization or causes prolongation of existing hospitalization
  4. Results in persistent or significant disability/incapacity
  5. May have caused a congenital anomaly/birth defect
  6. Requires intervention to prevent permanent impairment or damage
<span class="mw-page-title-main">Council for International Organizations of Medical Sciences</span> International non-governmental medical science organization

The Council for International Organizations of Medical Sciences (CIOMS) is an international non-governmental organization of 40 international, national, and associate member groups representing the biomedical science community. It was jointly established by the World Health Organization (WHO) and United Nations Educational, Scientific and Cultural Organization (UNESCO) in 1949 as a successor to the International Medical Congress that organized 17 conferences from 1867 until the 1913 outbreak of World War One.

<span class="mw-page-title-main">Metamizole</span> Medication

A drug known as metamizole or dipyrone is a painkiller, spasm reliever, and fever reliever. It is most commonly given by mouth or by intravenous infusion. It belongs to the ampyrone sulfonate family of medicines and was patented in 1922. Metamizole is marketed under various trade names. It was first used medically in Germany under the brandname "Novalgin".

<span class="mw-page-title-main">Uppsala Monitoring Centre</span>

Uppsala Monitoring Centre (UMC), located in Uppsala, Sweden, is the field name for the World Health Organization Collaborating Centre for International Drug Monitoring. UMC works by collecting, assessing and communicating information from member countries' national pharmacovigilance centres in regard to the benefits, harm, effectiveness and risks of drugs.

Postmarketing surveillance (PMS), also known as post market surveillance, is the practice of monitoring the safety of a pharmaceutical drug or medical device after it has been released on the market and is an important part of the science of pharmacovigilance. Since drugs and medical devices are approved on the basis of clinical trials, which involve relatively small numbers of people who have been selected for this purpose – meaning that they normally do not have other medical conditions which may exist in the general population – postmarketing surveillance can further refine, or confirm or deny, the safety of a drug or device after it is used in the general population by large numbers of people who have a wide variety of medical conditions.

EudraVigilance is the European data processing network and management system for reporting and evaluation of suspected adverse reactions to medicines which have been authorised or being studied in clinical trials in the European Economic Area (EEA). The European Medicines Agency (EMA) operates the system on behalf of the European Union (EU) medicines regulatory network.

Pharmacoepidemiology is the study of the uses and effects of drugs in well-defined populations.

The following outline is provided as an overview of and topical guide to clinical research:

<span class="mw-page-title-main">Syed Ziaur Rahman</span> Indian pharmacologist (born 1972)

Syed Ziaur Rahman is a permanent member of 'Board of Trustees' and Chair of the Advisory Council, International Association of Medical Colleges (IAOMC). He also serves as elected secretary of IAOMC and Society of Pharmacovigilance, India (SoPI).

VigiBase is a World Health Organization's (WHO) global Individual Case Safety Report (ICSR) database that contains ICSRs submitted by the participating member states enrolled under WHO's international drug monitoring programme. It is the single largest drug safety data repository in the world. Since 1978, the Uppsala Monitoring Centre on behalf of WHO, have been maintaining VigiBase. Vigibase is used to obtain the information about a safety profile of a medicinal product. These data are used by pharmaceutical industries, academic institutions and regulatory authorities for statistical signal detection, updating periodic reports, ICSR comparisons with company databases and studying the reporting patterns. The data is collected from each of its 110 member states which currently comprises to over 10 million ICSRs. About a hundred thousand ICSRs are added each year.

<span class="mw-page-title-main">Clinical trials in India</span>

Clinical trials in India refers to clinical research in India in which researchers test drugs and other treatments on research participants. NDCTR 2019 and section 3.7.1 to 3.7.3 of ICMR guidelines requires that all researchers conducting a clinical trial must publicly document it in the Clinical Trials Registry - India.

<i>Swasthya Adhikar Manch v. Union of India</i> 2013 Supreme Court of India case

Swasthya Adhikar Manch v. Union of India was a 2013 court case in which Swasthya Adhikar Manch requested additional government regulation in the management of clinical trials. The court found in favor of that organization and ordered regulation.

Nilima Arun Kshirsagar FACCP, FRCP, FNAMS FNAS is an Indian clinical pharmacologist who developed and patented liposomal amphotericin B and its drug delivery system in 1993. She is the former dean of King Edward Memorial Hospital and Seth Gordhandas Sunderdas Medical College. She is the national chairperson in clinical pharmacology at Indian Council of Medical Research (ICMR) and president of the South Asian chapter of the American college of clinical pharmacology. She is a Member of the WHO Committees on Product development and Drug statistics Methodology.

Haggar Hilda Ampadu is a Ghanaian regulator, pharmacoepidemiologist and policy advocate. As of 2019, she is the Inspector-General of Schools of the National Schools Inspectorate Authority under Ghana's Ministry of Education.

References

  1. 1 2 3 4 Indian Pharmacopoeia Commission (2014). "Guidance Document for Spontaneous Adverse Drug Reaction Reporting" (PDF). p. 2.
  2. 1 2 3 4 5 6 7 8 Thatte, Urmila M.; Chaudhari, Nayan L.; Gogtay, Nithya J. (October 2018). "Pharmacovigilance Program of India: history, evolution and current status". Adverse Drug Reaction Bulletin. 312 (1): 1207–1210. doi:10.1097/FAD.0000000000000036. S2CID   81421623.
  3. 1 2 3 4 5 6 Kalaiselvan, V; Thota, P; Singh, GN (2016). "Pharmacovigilance Programme of India: Recent developments and future perspectives". Indian Journal of Pharmacology. 48 (6): 624–628. doi: 10.4103/0253-7613.194855 . PMC   5155460 . PMID   28066097.
  4. 1 2 3 Lihite, Ratan J.; Lahkar, Mangala (22 September 2015). "An update on the Pharmacovigilance Programme of India". Frontiers in Pharmacology. 6: 194. doi: 10.3389/fphar.2015.00194 . PMC   4585088 . PMID   26441651.
  5. ↑ Gupta, YK; Padhy, BM (June 2011). "India's growing participation in global clinical trials". Trends in Pharmacological Sciences. 32 (6): 327–9. doi:10.1016/j.tips.2011.02.017. PMID   21489644.
  6. ↑ Dylan Fernandes, S; Anoop, NV; Castelino, LJ; Narayana Charyulu, R (January 2019). "A national approach to pharmacovigilance: The case of India as a growing hub of global clinical trials". Research in Social & Administrative Pharmacy. 15 (1): 109–113. doi:10.1016/j.sapharm.2018.03.061. PMID   29602659. S2CID   4507185.
  7. 1 2 World Health Organization (2017). "WHO Collaborating Centre for Pharmacovigilance in Public Health Programmes and Regulatory Services". World Health Organization. Archived from the original on 26 February 2018.
  8. 1 2 3 Jose, Jobin; Rafeek, Naziya Refi (November 2019). "Pharmacovigilance in India in Comparison With the USA and European Union: Challenges and Perspectives". Therapeutic Innovation & Regulatory Science. 53 (6): 781–786. doi:10.1177/2168479018812775. PMID   30554527. S2CID   58768139.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.